Robinhood shares gain on Q2 beat, as user and crypto growth accelerate
Investing.com - Revvity, Inc. (NYSE:RVTY) on Monday reported second-quarter earnings that exceeded analyst expectations, with revenue growth across both its business segments despite challenging market conditions.
The life sciences and diagnostics company posted adjusted earnings per share of $1.18, surpassing the analyst estimate of $1.14, while revenue reached $720 million, above the consensus estimate of $710.39 million.
Revenue increased 4% on a reported basis and 3% organically compared to the same period last year when the company generated $692 million.
The company’s shares rose 1.2% following the announcement.
"The power of Revvity’s transformation and consistent execution were evident in our second-quarter performance, enabling us to exceed expectations despite the evolving market environment," said Prahlad Singh, president and chief executive officer of Revvity.
The Life Sciences segment led growth with revenue of $366 million, up 5% (4% organically) YoY, while the Diagnostics segment posted revenue of $354 million, increasing 3% (2% organically) from the same quarter last year.
Despite the revenue growth, adjusted operating income declined slightly to $192 million from $199 million a year ago, with adjusted operating profit margin decreasing to 26.6% from 28.8% in the prior-year period.
For fiscal year 2025, Revvity updated its guidance, now expecting revenue between $2.84-$2.88 billion, reflecting 2-4% organic growth.
The company also adjusted its full-year EPS forecast to $4.85-$4.95, with the midpoint of $4.90 slightly below the analyst consensus of $4.93.
The company attributed its performance to a strong innovation pipeline and disciplined operational focus, positioning it for long-term value creation despite ongoing market challenges.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.